SAN DIEGO, Oct. 16 /PRNewswire/ -- TargeGen, Inc. today announced that the Company has received a "Notice Of Allowance" from the USPTO pertaining to its U.S. Patent application covering TG100-115 and related compounds. TG100-115 is an internally discovered, selective PI3 kinase inhibitor that has demonstrated the ability to suppress vascular leakage (edema), inflammation and thus significantly reduce infarct size and reperfusion injury in pre-clinical models of acute myocardial infarction (heart attack). A Phase I/II multi-center clinical trial involving TG100-115 is currently in progress in the U.S. and Canada with completion expected before the end of Q1 2007.
(Logo: http://www.newscom.com/cgi-bin/prnh/20030430/TARGEGENLOGO)
Following a heart attack, the condition of hypoxia (oxygen deprivation) activates kinase signaling cascades which cause biochemical changes to blood vessels which permit leakage. The leakage out of the vasculature contributes to microcirculatory collapse, inflammation, reperfusion injury, heart tissue damage and ultimate infarct size. TG100-115 has been designed to selectively block vascular leakage and inflammation for up to six hours after an ischemic event. Acute Myocardial Infarction (AMI) is the number one disease related cause of death in the developed world with approximately 2.1 million new cases per year in the USA, Western Europe and Japan.
In addition to TG100-115, TargeGen is developing TG100801, a topically applied treatment for AMD and other eye diseases. A Phase I clinical trial involving TG100801 is scheduled to start later this year. The Company also has preclinical programs to develop therapies for certain forms of leukemia and myeloproliferative diseases.
About TargeGen, Inc.
TargeGen, Inc. is a privately held vascular biology-focused biopharmaceutical company based in San Diego, CA. TargeGen is currently working on the development of four internally discovered novel small molecule therapeutics to treat certain debilitating eye diseases, cardiovascular disease, leukemia and myeloproliferative diseases.
Photo: http://www.newscom.com/cgi-bin/prnh/20030430/TARGEGENLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comTargeGen, Inc.CONTACT: TargeGen, Inc., +1-858-678-0760, or fax, +1-858-678-0762,info@targegen.com
Web site: http://www.targegen.com/
